Tina Flatau

Tina Flatau has a long and varied work experience in the life sciences industry. Tina began their career in 2005 as the eDMS Project Leader for MedImmune in the UK. Tina then moved to UCB Celltech as a Transformation Leader, Research to Development in the same year. In 2008, they became an Advisor for Ipsat Therapies in Helsinki and an R&D consultant for Leiden (Biopharmaceutical R&D). Tina then joined MEDANNEX LIMITED & OncoBioPharm Ltd as Managing Director & Advisory in 2016. That same year, they also became Managing Director of aTen Therapeutics Ltd. In 2010, they joined Prosensa Therapeutics B.V. as VP Alliances and Project Management, where they worked through processes of due diligence and licensing/ collaboration agreements, of shaping and prioritizing the R&D portfolio to a sustainable pipeline, and led the business side of SEC submissions to a successful IPO (Initial Public Offering of share capital) on NASDAQ in 2013. In 2017, they became a Trustee for Action Duchenne and a Trustee (R&D, liason with life science industry developers). Tina is currently the Chief Business Officer for Sixfold Bioscience, a position they have held since 2021.

Tina Flatau received their B Pharm class I from Chelsea School of Pharmacy in 1984, after studying Pharmacy and pharmacology from 1981 to 1984. Tina then went on to pursue a PhD in Pharmaceutics, Pharmacology, and Pharmacy at King's College London from 1985 to 1989.